Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Lexaria Bioscience Corp WT (LEXXW)

Lexaria Bioscience Corp WT (LEXXW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 ACCESS Newswire - Tue Dec 23, 2025

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus®

LEXXW : 0.0012 (-77.36%)
LEXX : 0.6163 (+2.38%)
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock ACCESS Newswire - Mon Apr 28, 2025

KELOWNA, BC / ACCESS Newswire / April 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.6163 (+2.38%)
Lexaria Announces $2 Million Registered Direct Offering of Common Stock ACCESS Newswire - Fri Apr 25, 2025

KELOWNA, BC / ACCESS Newswire / April 25, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.6163 (+2.38%)
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology ACCESS Newswire - Wed Apr 23, 2025

Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry

LEXXW : 0.0012 (-77.36%)
LEXX : 0.6163 (+2.38%)
Lexaria Updates its Ongoing Human Study GLP-1-H24-4 ACCESS Newswire - Thu Apr 3, 2025

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss

LEXXW : 0.0012 (-77.36%)
LEXX : 0.6163 (+2.38%)
Lexaria's Human GLP-1 Study #5 Begins Dosing ACCESS Newswire - Wed Apr 2, 2025

Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide

LEXXW : 0.0012 (-77.36%)
LEXX : 0.6163 (+2.38%)
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R) ACCESS Newswire - Tue Mar 18, 2025

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®

LEXXW : 0.0012 (-77.36%)
LEXX : 0.6163 (+2.38%)
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience ACCESS Newswire - Thu Feb 27, 2025

Lexaria executing a triple-pronged strategy in obesity and diabetes

LEXXW : 0.0012 (-77.36%)
LEXX : 0.6163 (+2.38%)
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm ACCESS Newswire - Mon Feb 24, 2025

5th study arm in 12-week Phase 1b Study receives lead clinical site approval

LEXXW : 0.0012 (-77.36%)
LEXX : 0.6163 (+2.38%)
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide ACCESS Newswire - Thu Feb 20, 2025

Pursuing the world's first-ever orally-dosed liraglutide

LEXXW : 0.0012 (-77.36%)
LEXX : 0.6163 (+2.38%)

Barchart Exclusives

This High-Yield Home Improvement Stock Just Hiked Its Dividend by 4.2% Barchart - 1 hour ago
Lowe’s Companies raised its quarterly dividend by 4.2% to $1.25 per share, marking its 55th consecutive year of increases and reinforcing its status as a Dividend King amid a challenging housing market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.